Utility of dynamic contrast enhancement for clinically significant prostate cancer detection

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection

Abstract Objective This study aimed to evaluate the association of dynamic contrast enhancement (DCE) with clinically significant prostate cancer (csPCa, Gleason Grade Group ≥2) and compare biparametric magnetic resonance imaging (bpMRI) and multiparametric MRI (mpMRI) nomograms. Subjects/patients a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Eric V. Li, Sai K. Kumar, Jonathan A. Aguiar, Mohammad R. Siddiqui, Clayton Neill, Zequn Sun, Edward M. Schaeffer, Anugayathri Jawahar, Ashley E. Ross, Hiten D. Patel
Format:	Article
Language:	English
Published:	Wiley 2024-09-01
Series:	BJUI Compass
Subjects:	diagnosis dynamic contrast enhancement nomogram prostate cancer prostate MRI risk stratification
Online Access:	https://doi.org/10.1002/bco2.415
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differentiating clinically significant prostate cancer from clinically insignificant prostate cancer using qualitative and semi-quantitative indices of dynamic contrast-enhanced MRI
by: Tsutomu Tamada, et al.
Published: (2024-12-01)

Construction of a clinically significant prostate cancer risk prediction model based on traditional diagnostic methods
by: Wen-Tong Ji, et al.
Published: (2024-12-01)

Systematic and Targeted Prostate Biopsy: a Five-Year Experience in a High-Volume Center
by: Toni Zekulić, et al.
Published: (2024-01-01)

Clinical assessment of urinary prostate cancer antigen 3 in Chinese population: a large-scale, prospective and multicenter study
by: Xuan Shu, et al.
Published: (2024-12-01)

The Effect of Pre-Biopsy Prostate MRI on the Congruency and Upgrading of Gleason Grade Groups Between Prostate Biopsy and Radical Prostatectomy
by: Peter Stapleton, et al.
Published: (2024-12-01)

Development of novel nomograms for predicting prostate cancer in biopsy-naive patients with PSA < 10 ng/ml and PI-RADS ≤ 3 lesions
by: Jia-gui Chai, et al.
Published: (2025-01-01)

Personalized optimization of systematic prostate biopsy core number based on mpMRI radiomics features: a large-sample retrospective analysis
by: Zhenlin Chen, et al.
Published: (2025-01-01)

Targeted Prostate Health Checks, a novel system to identify men with prostate cancer—A pilot study
by: Stephen Langley, et al.
Published: (2024-10-01)

Nomograms and scoring system for forecasting overall and cancer‐specific survival of patients with prostate cancer
by: Yuan Zhou, et al.
Published: (2023-02-01)

Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI
by: Laura J. Jensen, et al.
Published: (2024-11-01)

Integration of Genomic Tests in Prostate Cancer Care: Implications for Clinical Practice and Patient Outcomes
by: Christos Roidos, et al.
Published: (2024-12-01)

Comparisons of three scoring systems based on biparametric magnetic resonance imaging for prediction of clinically significant prostate cancer
by: Wei Li, et al.
Published: (2024-12-01)

Biparametric MRI-based radiomics for noninvastive discrimination of benign prostatic hyperplasia nodules (BPH) and prostate cancer nodules: a bio-centric retrospective cohort study
by: Yangbai Lu, et al.
Published: (2025-01-01)

‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
by: Ryan Sutherland, et al.
Published: (2024-06-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer
by: Yi Wu, et al.
Published: (2025-01-01)

Value of Systematic and MRI‐Ultrasound Fusion Prostate Biopsy in Different Prostate Specific Antigen (PSA) Levels
by: Solmaz Ohadian Moghadam, et al.
Published: (2025-01-01)

The Integral Role and Clinical Significance of Metabolic Profiling in Prostate Cancer: A Narrative Review
by: Valentin Nikolaevich Pavlov, et al.
Published: (2024-07-01)

Repeatability, reproducibility, and the effects of radiotherapy on radiomic features of lowfield MR-LINAC images of the prostate
by: Parker Anderson, et al.
Published: (2025-01-01)

Optimizing radiomics for prostate cancer diagnosis: feature selection strategies, machine learning classifiers, and MRI sequences
by: Eugenia Mylona, et al.
Published: (2024-11-01)

Optimizing Multiparametric MRI Protocols for Prostate Cancer Detection: A Comprehensive Assessment Aligned with PI‐RADS Guidelines
by: Mohammad Hossein Jamshidi, et al.
Published: (2024-11-01)

Comparison of tracer kinetic models in differentiating malignant from normal prostate tissue using dynamic contrast-enhanced MRI
by: Hongjiang Zhang, et al.
Published: (2024-12-01)

Association between prostate-specific antigen density and prostate cancer prediction among Nigerian men
by: Abudu EK, et al.
Published: (2025-01-01)

Risk Calculator Strategy Before Magnetic Resonance Imaging Stratification for Biopsy-naïve Men with Suspicion for Prostate Cancer: A Cost-effectiveness Analysis
by: Konstantius R.V. Straat, et al.
Published: (2024-12-01)

Severe Xanthogranulomatous prostatitis mimicking prostate cancer: a case report
by: Wael Abdo Hassan, et al.
Published: (2024-12-01)

The Novel Histological Prostatic Inflammation Score Helps Defining the Association Between Stromal and Glandular Inflammation with the Risk of Prostate Cancer at Prostate Biopsy
by: Ugo Giovanni Falagario, et al.
Published: (2025-01-01)

The factors impacting on Gleason score upgrading in prostate cancer with initial low Gleason scores
by: Tzu-Heng Huang, et al.
Published: (2025-02-01)

Clinical significance of high grade and low grade prostate intraepithelial neoplasia
by: M.P. Melnychuk
Published: (2021-06-01)

Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making
by: Antonela Njavro, et al.
Published: (2024-01-01)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024-11-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Correlation of clinically significant prostate cancer sites across multiparametric MRI, prostate biopsy, and whole-mount pathology for optimal prostate biopsy strategy
by: Matteo Pacini, et al.
Published: (2025-02-01)

3D-AttenNet model can predict clinically significant prostate cancer in PI-RADS category 3 patients: a retrospective multicenter study
by: Jie Bao, et al.
Published: (2025-01-01)

Giant sarcoma of the prostate stroma: Clinical, radiological and histopathological analysis of a rare prostatic cancer
by: Alan de Jesus Martinez Salas, et al.
Published: (2024-11-01)

A Prospective Comparison of MRI-Guided Targeted Biopsy with 12-Core Transrectal Ultrasound-Guided Systematic Biopsy in the Diagnosis of Clinically Significant Prostate Cancer: An Indian Experience
by: Arjunlokesh Netaji, et al.

Prostatitis, benign prostatic hyperplasia, and prostate cancer: a bidirectional Mendelian randomization study and clinical implications for these patients’ populations
by: Yi Wang, et al.
Published: (2024-12-01)

Clinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction
by: Hayato Takeda, et al.
Published: (2024-11-01)

Oncological outcomes after radical prostatectomy of localized prostate cancer: stratified by magnetic resonance imaging and risk classification
by: Gyoohwan Jung, et al.
Published: (2024-12-01)

Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4-10 ng/ml)
by: Abdulsattar J. Ali, et al.
Published: (2020-12-01)

COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY
by: M. E. Topuzov, et al.
Published: (2015-10-01)